Germany · Delayed Price · Currency is EUR adesso SE Earnings Call Transcripts
Fiscal Year 2025
-
Achieved 14% organic sales growth and 30% EBITDA increase in 2025, with strong sector diversification and robust performance in Germany. Guidance for 2026 anticipates further revenue and earnings growth, with AI-driven projects and public sector demand as key drivers.
-
Revenue and EBITDA grew 13% and 17% year-over-year, respectively, with strong sector diversification and robust growth in insurance, health, and utilities. Despite a challenging German market and increased competition, full-year guidance is confirmed, with Q4 expected to deliver the necessary results.
-
Sales grew 12% to €709.5M and EBITDA rose 34% to €37.2M, with strong sector diversification and improved margins. On track for full-year guidance, despite macroeconomic headwinds and negative cash flow driven by investments and acquisitions.
-
Q1 2025 saw 11% organic revenue growth and stable operating results despite macroeconomic headwinds. Guidance for the year is confirmed, with strong sectoral and regional performance, cautious hiring, and ongoing process improvements expected to boost margins in H2.
Fiscal Year 2024
-
Organic sales rose 14% to €1.3B with EBITDA up 23%, but margin remains below target. 2025 guidance anticipates 4–12% revenue growth, improved margins, and a higher dividend, with public sector recovery expected in H2.
-
Q3 delivered strong profitability gains, with EBITDA margin up to 11.8% and 15% organic sales growth. The company is on track to meet full-year guidance, driven by improved utilization and robust sector performance, especially in healthcare and utilities.
-
Sales grew 16% year-over-year to EUR 631.1 million, driven by organic growth, but profitability was impacted by low utilization and weak license sales in the solution business. EBITDA guidance for 2024 was lowered, though sales targets remain intact, with H2 expected to be stronger.